Physician profile
Antonio Monzon
NPI 1184663585
$880.89
in general payments reported to CMS, 2019-2025
20 companies · $23.84 in 2025
The $23.84 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.71 · 2020: $149 · 2021: $334 · 2022: $254 · 2023: $19.71 · 2024: $73.74 · 2025: $23.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $200.98 | 2021-2022 | |
| Therapeuticsmd, INC. | $95.64 | 2019-2022 | |
| Abbvie INC. | $91.88 | 2020-2021 | |
| Hologic Sales and Service, LLC | $88.78 | 2020-2024 | Myosure Tissue Removal Device, Omni Hysteroscope |
| Bayer Healthcare Pharmaceuticals INC. | $67.24 | 2020-2022 | |
| Astellas Pharma US INC | $64.90 | 2022-2025 | Veozah |
| Pfizer INC. | $40.72 | 2022 | |
| Virtus Pharmaceuticals LLC | $30.15 | 2021 | |
| Evofem Biosciences, INC. | $24.49 | 2021 | |
| Mayne Pharma Commercial LLC | $22.34 | 2021 | |
| Meditrina | $21.06 | 2020 | |
| Sumitomo Pharma America, INC. | $19.71 | 2023 | Myfembree |
| Agile Therapeutics, INC. | $19.00 | 2021 | |
| Exeltis, USA INC. | $16.30 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.61 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $14.03 | 2021 | |
| Coopersurgical, INC. | $13.84 | 2024 | Paragard T 380a |
| Duchesnay USA Incorporated | $12.76 | 2019 | |
| Urovant Sciences INC | $11.39 | 2021 | |
| Millicent US INC | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Monzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.